Paul Tudor Jones’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$62.4M Buy
394,500
+103,000
+35% +$13.9M 0.09% 161
2026
Q1
$37.2M Sell
291,500
-406,000
-58% -$50.7M 0.07% 210
2025
Q4
$85M Buy
697,500
+258,300
+59% +$29.6M 0.16% 86
2025
Q3
$44M Buy
439,200
+1,700
+0.4% +$153K 0.08% 199
2025
Q2
$36.3M Buy
437,500
+32,500
+8% +$2.59M 0.08% 182
2025
Q1
$32.8M Buy
405,000
+240,000
+145% +$21.5M 0.11% 113
2024
Q4
$14.9M Buy
+165,000
New +$16M 0.06% 217

Other funds holding XBI

Paul Tudor Jones's XBI Position: Q2 2026 in Review

Paul Tudor Jones opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 502,000 shares worth $79.4M. The stake represents 0.11% of the portfolio and ranks #119 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in XBI as recently as Q2 2025.

Paul Tudor Jones first reported a position in XBI in Q4 2016 and has held it in 11 quarters since. 931 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Paul Tudor Jones held 502,000 shares of State Street SPDR S&P Biotech ETF worth $79.4M as of Q2 2026.
  • State Street SPDR S&P Biotech ETF was a new Paul Tudor Jones position in Q2 2026.
  • State Street SPDR S&P Biotech ETF made up 0.11% of Paul Tudor Jones's portfolio in Q2 2026, its #119 holding.
  • Paul Tudor Jones first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and has held it in 11 quarters since.
  • 931 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.